Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

MMP23B expression and protein levels in blood and urine are associated with bladder cancer.

Allione A, Pardini B, Viberti C, Giribaldi G, Turini S, Di Gaetano C, Guarrera S, Cordero F, Oderda M, Allasia M, Gontero P, Sacerdote C, Vineis P, Matullo G.

Carcinogenesis. 2018 Jul 20. doi: 10.1093/carcin/bgy098. [Epub ahead of print]

PMID:
30052775
2.

microRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes.

Pardini B, Cordero F, Naccarati A, Viberti C, Birolo G, Oderda M, Di Gaetano C, Arigoni M, Martina F, Calogero RA, Sacerdote C, Gontero P, Vineis P, Matullo G.

Oncotarget. 2018 Apr 17;9(29):20658-20669. doi: 10.18632/oncotarget.25057. eCollection 2018 Apr 17.

3.

DNA methylation profiling of asbestos-treated MeT5A cell line reveals novel pathways implicated in asbestos response.

Casalone E, Allione A, Viberti C, Pardini B, Guarrera S, Betti M, Dianzani I, Aldieri E, Matullo G.

Arch Toxicol. 2018 May;92(5):1785-1795. doi: 10.1007/s00204-018-2179-y. Epub 2018 Mar 9.

PMID:
29523930
4.

The prognostic value of basal DNA damage level in peripheral blood lymphocytes of patients affected by bladder cancer.

Allione A, Pardini B, Viberti C, Oderda M, Allasia M, Gontero P, Vineis P, Sacerdote C, Matullo G.

Urol Oncol. 2018 May;36(5):241.e15-241.e23. doi: 10.1016/j.urolonc.2018.01.006. Epub 2018 Feb 14.

PMID:
29426697
5.

Increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of bladder cancer.

Pardini B, Viberti C, Naccarati A, Allione A, Oderda M, Critelli R, Preto M, Zijno A, Cucchiarale G, Gontero P, Vineis P, Sacerdote C, Matullo G.

Br J Cancer. 2017 Jan 17;116(2):202-210. doi: 10.1038/bjc.2016.411. Epub 2016 Dec 13.

6.

Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.

Critelli R, Fasanelli F, Oderda M, Polidoro S, Assumma MB, Viberti C, Preto M, Gontero P, Cucchiarale G, Lurkin I, Zwarthoff EC, Vineis P, Sacerdote C, Matullo G, Naccarati A.

Oncotarget. 2016 Oct 11;7(41):67435-67448. doi: 10.18632/oncotarget.11883.

7.

H2AX phosphorylation level in peripheral blood mononuclear cells as an event-free survival predictor for bladder cancer.

Turinetto V, Pardini B, Allione A, Fiorito G, Viberti C, Guarrera S, Russo A, Anglesio S, Ruo Redda MG, Casetta G, Cucchiarale G, Destefanis P, Oderda M, Gontero P, Rolle L, Frea B, Vineis P, Sacerdote C, Giachino C, Matullo G.

Mol Carcinog. 2016 Nov;55(11):1833-1842. doi: 10.1002/mc.22431. Epub 2015 Nov 19.

8.

Comparison between different software programs and post-processing techniques for the MRI quantification of liver iron concentration in thalassemia patients.

Bacigalupo L, Paparo F, Zefiro D, Viberti CM, Cevasco L, Gianesin B, Pinto VM, Rollandi GA, Wood JC, Forni GL.

Radiol Med. 2016 Oct;121(10):751-62. doi: 10.1007/s11547-016-0661-2. Epub 2016 Jun 22.

PMID:
27334009
9.

Shorter leukocyte telomere length is independently associated with poor survival in patients with bladder cancer.

Russo A, Modica F, Guarrera S, Fiorito G, Pardini B, Viberti C, Allione A, Critelli R, Bosio A, Casetta G, Cucchiarale G, Destefanis P, Gontero P, Rolle L, Zitella A, Fontana D, Frea B, Vineis P, Sacerdote C, Matullo G.

Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2439-46. doi: 10.1158/1055-9965.EPI-14-0228. Epub 2014 Sep 18.

10.

Early results from the Euromir 95 experiment programme.

Stevenson T, Strode J, Viberti C.

ESA Bull. 1996 Nov;88:25-32.

PMID:
11541438
11.

The challenge of the EuroMir 95 technology experiments.

Viberti C.

ESA Bull. 1996 Aug;87:6 p..

PMID:
15008199
12.

Diabetic nephropathy: a preventable complication?

Viberti CG, Wiseman MJ, Bending JJ.

Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985;21:621-9. No abstract available.

PMID:
3991554

Supplemental Content

Loading ...
Support Center